news
Press release
 
October 31, 2013
Robotic-Assisted Coronary Angioplasty Procedure Shown Live at TCT Conference in San Francisco

More than 1,000 attendees witness precision stenting case performed with CorPath Vascular Robotics System

Waltham, MA – October 31, 2013Corindus Vascular Robotics the leader in precision vascular robotics, presented a live percutaneous coronary intervention (PCI), or coronary angioplasty, during the Transcatheter Cardiovascular Therapeutics (TCT) conference on Oct. 29. The procedure, led by Giora Weisz, director of Clinical Research at the Center for Interventional Vascular Therapy at Columbia University Medical Center, was transmitted live to more than 1,000 attendees of TCT at the Moscone Center in San Francisco, Calif.

The procedure was performed using the CorPath System, the first medical device to provide robotic precision and accuracy to coronary angioplasty to help optimize clinical outcomes. During the procedure, Dr. Weisz was seated in CorPath’s interventional cockpit, remotely controlling the advancement and placement of the balloon/stent catheter with exact, calculated movements. Using the system’s measurement function to select the proper length stent and place it in a blocked coronary artery, Dr. Weisz was precisely control the stent advancement. This particular case involved a patient with multiple risk factors and severe coronary artery disease (CAD) with multiple interventions.

“Robotic technology is changing the way interventional cardiologists conduct PCIs,” said Weisz. “I have performed more than 70 procedures using the CorPath and firmly believe in its potential to improve patient outcomes and provide a new standard of care in coronary angioplasty procedures. Presenting the case in real-time serves as an educational tool for interventional cardiologists, and an example of how to provide clinical applicability, utility and safety during a robotic PCI.”

The CorPath System is the first and only FDA-approved technology that enables precise, robotic-assisted angioplasties to open arteries and restore blood flow in patients with coronary artery disease. During a CorPath procedure, the interventional cardiologist sits in the radiation shielded interventional cockpit and advances stents and guidewires via a joy stick with millimeter-by-millimeter robotic precision. CorPath may improve clinical outcomes by enabling precise measurement of the anatomy, which could potentially lead to better stent placements.

“Working with Dr. Weisz and other global leaders in interventional cardiology procedures and science, Corindus is bringing unprecedented robotic precision to coronary angioplasty procedures to help optimize clinical outcomes and minimize associated costs,” said David Handler, President and CEO of Corindus Vascular Robotics. “By utilizing one stent per lesion, hospitals can minimize readmissions and other costs associated with improper stent placement.”

About Corindus Vascular Robotics, Inc.

Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath System is the first FDA-cleared medical device to bring robotic precision to interventional procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program."

For additional information, visit www.corindus.com, and follow @CorindusInc.

Forward Looking Statements

Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future event

Examples of such statements include statements:

  • that the level of precision that can be attained using the CorPath GRX technology, combined with the potential for remote capabilities in the future, will both expand and improve how patients are treated;
  • that Corindus has entered a transformational period with a focus on expanding its reach to partner with hospitals to build robotic programs globally;
  • that the successful completion of these procedures at Fu Wai Hospital is the first step in Corindus' growth strategy within China; and that
  • the precise positioning enhancements to the CorPath platform that allows physicians to adjust guide catheters during PCI procedures may expand the use of the CorPath GRX System to more complex cases.

Media Contacts:

Corindus Vascular Robotics, Inc.

Kate Stanton
(508) 653-3335 ext. 200
kate.stanton@corindus.com

Investor Contact:

Lynn Pieper Lewis
(415) 937-5402
ir@corindus.com
 
close the window

Please complete the form below in order to download the content.








right
close the window

Please complete the form below in order to download the content.







close the window

Please fill out this brief form to subscribe to our email newsletter.





close the window

Please complete the form below and a member of our Clinical team will contact you.






close the window

Please complete the form below in order to download the content.







close the window
Thank you for subscribing to our newsletter. You will now receive email updates from Corindus.